Data as of Q4 2025 (Dec 31, 2025)

Octagon Capital Advisors LP

โ€ขCIK: 1839435โ€ขFiling: Q4 2025

**Octagon Capital Advisors LP** manages $824M across a concentrated portfolio of 27 positions. The fund exhibits significant conviction in its top holdings, led by ABVX at $102.0M and DNTH at $99.6M. Further substantial allocations include COGT ($83.5M) and TSHA ($48.7M), indicating deep sector focus. This structure suggests a highly selective, large-cap growth mandate.

Total AUM
$798.8M
+ $24.9M in options
QoQ Performance
+24.7%
Positions
26
+ 1 option
Top 10 Concentration
67.4%
Latest Filing
Q4 2025

Top Holdings Allocation

ABVX
DNTH
COGT
TSHA
GOSS
KYMR
ABVX12.4%
DNTH12.1%
COGT10.1%
TSHA5.9%
GOSS5.2%
KYMR5.1%
AVBP4.8%
TRVI4.3%

๐Ÿ“ˆ Biggest Buys

CGONCALL
CG ONCOLOGY INC
NEW
3.0% of portfolio
ALMS
ALUMIS INC
NEW
3.0% of portfolio
PALI
PALISADE BIO INC
NEW
2.7% of portfolio
BIOA
BIOAGE LABS INC
NEW
2.6% of portfolio
RAPT
RAPT THERAPEUTICS INC
NEW
2.4% of portfolio

๐Ÿ“‰ Biggest Sells

ABVX
ABIVAX SA
-42.9%
12.4% of portfolio
COGT
COGENT BIOSCIENCES INC
-18.2%
10.1% of portfolio
GOSS
GOSSAMER BIO INC
-18.4%
5.2% of portfolio
DBVT
DBV TECHNOLOGIES S A
-43.6%
1.3% of portfolio
CNTA
CENTESSA PHARMACEUTICALS PLC
-9.6%
2.3% of portfolio

Sector Breakdown

Other100.0%

๐Ÿšช Exited Positionssold since Q3 2025

2GH
MERUS N V
SOLD
$29.0M
APLS
APELLIS PHARMACEUTICALS INC
SOLD
$20.4M
NUVB
NUVATION BIO INC
SOLD
$9.7M
MAZE
MAZE THERAPEUTICS INC
SOLD
$4.6M
NGNE
NEUROGENE INC
SOLD
$4.4M
+2 more exited positions

Changes from Q3 2025

NEW8 new positions
โ†‘2 increased
โ†“9 decreased

Historical Filings

Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023